Dementia-Related Psychosis Market Poised for Significant Expansion
The dementia-related psychosis market is projected to grow at a compound annual growth rate of 26.2% through 2036, driven by the increasing burden of dementia and emerging therapies.
The market for dementia-related psychosis is anticipated to experience substantial growth from 2026 to 2036, with an estimated compound annual growth rate (CAGR) of 26.2%. This expansion is primarily fueled by the rising prevalence of dementia and the emergence of novel therapeutic options, such as Acadia Pharmaceuticals' ACP-204 (Remlifanserin) and Bristol Myers Squibb's Xanomeline–trospium chloride (COBENFY).
Factors contributing to market growth also include improvements in dementia diagnosis and increased patient awareness. These elements are expected to collectively create a favorable environment for market expansion over the next decade.
The market analysis provides insights into market size, trends, drivers, and challenges, along with a review of companies focused on treating dementia-related psychosis. The successful development and accessibility of new treatments are identified as key determinants for the market's future trajectory.